Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia

BACKGROUND: Despite advances in targeted agent development, effective treatment of acute myeloid leukemia (AML) remains a major clinical challenge. The B-cell lymphoma-2 (BCL-2) inhibitor exhibited promising clinical activity in AML, acute lymphoblastic leukemia (ALL) and diffuse large B-cell lympho...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Wenwen, Huang, Shujuan, Ling, Qing, Mao, Shihui, Qian, Yu, Ye, Wenle, Li, Fenglin, Pan, Jiajia, Lin, Xiangjie, Huang, Jiansong, Huang, Xin, Zhai, Yifan, Sun, Jie, Jin, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258085/
https://www.ncbi.nlm.nih.gov/pubmed/35794605
http://dx.doi.org/10.1186/s12967-022-03497-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9258085/
https://www.ncbi.nlm.nih.gov/pubmed/35794605
http://dx.doi.org/10.1186/s12967-022-03497-2

Ejemplares similares